Product Center
The launch meeting of the Phase III clinical trial of the quadrivalent influenza virus subunit vaccine (aged 6-35 months) was successfully completed
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04
- Views:
(Summary description)In the old year, a thousand pieces of brocade have been showcased, and in the new year, we will make another hundred feet of progress! On January 31st, the kickoff meeting for the Phase III clinical t
The launch meeting of the Phase III clinical trial of the quadrivalent influenza virus subunit vaccine (aged 6-35 months) was successfully completed
(Summary description)In the old year, a thousand pieces of brocade have been showcased, and in the new year, we will make another hundred feet of progress! On January 31st, the kickoff meeting for the Phase III clinical t
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04 16:17
- Views:
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
